STOCK TITAN

Armistice Capital reports 2.76M-share stake in Supernus (SUPN)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Supernus Pharmaceuticals Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,764,000 shares, equal to 4.82% of the common stock as of 12/31/2025. The filing states Armistice Capital exercises voting and investment power under an Investment Management Agreement, while the Master Fund disclaims beneficial ownership.

Positive

  • None.

Negative

  • None.

Insights

Filing documents a passive holding below 5% with manager attribution.

The Schedule 13G/A reports 2,764,000 shares (4.82%) owned as of 12/31/2025 and classifies the position under "Ownership of 5 Percent or Less of a Class." The statement attributes voting and investment power to Armistice Capital per an Investment Management Agreement.

Filing also records the Master Fund's explicit disclaimer of beneficial ownership due to its inability to vote or dispose of the shares under that agreement; timing and any planned transactions are not stated in the excerpt.

Ownership level is informative but routine; not materially dilutive.

The reported 4.82% stake is below the 5% threshold noted in the filing and is presented as shared voting/dispositive power of 2,764,000 shares. The filing is an ownership disclosure, not a sale or purchase notice.

Holder attribution to Armistice and the managing member, Steven Boyd, is disclosed; subsequent filings would be required to show any change in position.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What does the Armistice 13G/A say about SUPN ownership?

The filing reports 2,764,000 shares, representing 4.82% of common stock as of 12/31/2025. It attributes shared voting and dispositive power to Armistice Capital under an Investment Management Agreement while the Master Fund disclaims beneficial ownership.

Who is reported as the beneficial owner in the SUPN 13G/A?

Armistice Capital, LLC is reported as exercising voting and investment power over the shares, and Steven Boyd is named as managing member; both are joint reporting persons for the 2,764,000-share position.

Does the Master Fund claim beneficial ownership of the SUPN shares?

No. The filing states the Master Fund is the direct holder but "disclaims beneficial ownership" because it lacks the ability to vote or dispose of the securities due to its Investment Management Agreement with Armistice Capital.

Is the reported SUPN stake above the 5% reporting threshold?

No. The Schedule 13G/A classifies the position as "Ownership of 5 Percent or Less of a Class," reporting 4.82% ownership, which is below the 5% threshold defined in the filing.

What voting and disposition powers are reported for the SUPN shares?

The filing shows 0 shares of sole voting or dispositive power and 2,764,000 shares of shared voting and dispositional power, reflecting Armistice Capital's role under the Investment Management Agreement.
Supernus Pharma

NASDAQ:SUPN

SUPN Rankings

SUPN Latest News

SUPN Latest SEC Filings

SUPN Stock Data

2.96B
54.86M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ROCKVILLE